glp-1 receptor agonist kidney outcomes semaglutide flow trial 2024 results in patients with overweight or obesity and chronic disease without diabetes: a randomized double-blind placebo-controlled clinical Kidney and Cardiovascular Outcomes Among
Description
[DOI] [PubMed] [Google Scholar] 391.Panjwani N., Mulvihill E.E., Longuet C., Yusta B., Campbell J.E., Brown T.J
10.1185/03007990802418851 42 Del PratoS
A., Eslaminejad, T., & Nematollahi-Mahani, S
In addition to its many effects on glucose metabolism, it also influences various physiologic processes, including the regulation of appetite, gastrointestinal motility, and cardiovascular benefits [1]
2020) While there have been improvements in cardiometabolic factors in response to GCGR activation such as body weight, steatohepatitis, and glucose homeostasis, there are concerns due to the potential impact of GCGR agonism on the heart
Dipeptidyl peptidase 4 distribution in the human respiratory tract: implications for the Middle East respiratory syndrome
